Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. Show more
Location: 75 Hayden Avenue, Lexington, MA, 02421, United States | Website: https://www.voyagertherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
193.1M
52 Wk Range
$2.65 - $9.55
Previous Close
$3.55
Open
$3.57
Volume
830,035
Day Range
$3.46 - $3.62
Enterprise Value
-21.93M
Cash
236M
Avg Qtr Burn
-27.99M
Insider Ownership
16.59%
Institutional Own.
63.43%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AAV Capsids (Pfizer) Details Neurological disorder | Phase 1 Update | |
AAV Capsids + ZF-TRs (Sangamo) Details Prion disease | Phase 1 Initiation | |
AAV Capsids (Novartis) Details Cardiovascular disease , Neurological disorder | Phase 1 Initiation | |
AAV Capsids Details Cardiovascular disease , Neurological disorder | Phase 1 Initiation | |
VY7523 (formerly VT- TAU01) [anti-tau antibody] Details Alzheimer's disease | Phase 1a Data readout | |
VY1706 (Tau-silencing Gene Therapy) Details No identified indication yet | IND Submission | |
GBA1 gene therapy program Details Parkinson's disease, Central nervous system illness | IND Submission | |
VY9323 (SOD1 silencing gene therapy) Details Neurodegenerative disease, Amyotrophic lateral sclerosis | Failed Discontinued | |
VY-HTT01 Details Huntington's disease | Failed Discontinued | |
VY-AADC (NBIb-1817) Details Parkinson's disease, Central nervous system illness | Failed Discontinued |